Dutch Judges To Decide Whether Humira ’s Price And AbbVie’s Profits Are “Too High”
In a unique challenge to drug makers, the Dutch Pharmaceutical Accountability Foundation is taking the manufacturer of Humira, AbbVie, to court for alleged excessive profiteering. The Foundation accuses AbbVie of engaging in “unfair, excessive pricing practices” regarding its drug, Humira. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 1, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
Big Pharma ’s Patent Abuses Are Fueling the Drug Pricing Crisis
Addressing the nation during his State of the Union speech, President Joe Biden took aim at an injustice that touches the lives of most Americans—the absurdly high cost of prescription drugs. As the president laid out, the U.S. has the highest costs on drugs in the world. Biden vowed to take action, which will undoubtedly lead to the pharmaceutical industry’s lobbyists, lawyers, and paid-for allies doubling down on their frenzied efforts to derail newly enacted drug pricing reforms in order to protect the industry’s power and profits. As important as these pricing reforms are, they target only certain par...
Source: TIME: Health - February 24, 2023 Category: Consumer Health News Authors: Tahir Amin and David Mitchell Tags: Uncategorized freelance health Health Care Source Type: news
New Influx of Humira Biosimilars May Not Drive Immediate Change New Influx of Humira Biosimilars May Not Drive Immediate Change
As many as 8 to 10 adalimumab biosimilars are anticipated to come on the market this year, giving mainstay drug Humira some vigorous competition.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 24, 2023 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
Alkem subsidiary Enzene launches adalimumab biosimilar in India
Enzene or its parent Alkem which is commercialising the drug didn't announce the price, but said it would be competitively priced. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 23, 2023 Category: Pharmaceuticals Source Type: news
AbbVie accused of overcharging Dutch for flagship drug Humira
Drugmaker taken to court by public interest group for abusing market position and profiteering (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 21, 2023 Category: Pharmaceuticals Source Type: news
Secukinumab Shows Benefit for Hidradenitis Suppurativa at 1 Year Secukinumab Shows Benefit for Hidradenitis Suppurativa at 1 Year
Currently, the tumor necrosis factor inhibitor adalimumab is the only biologic therapy approved for the treatment of moderate to severe hidradenitis suppurativa.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 14, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Amgen Adopts A Two-Price Strategy For The U.S. ’s First Marketed Humira-Referenced Biosimilar, Amjevita
In the case of Amjevita, the two-price approach highlights the lack of transparency in the healthcare system as well as the incredibly confusing way in which drugs are priced in the U.S. Rebates obfuscate an already bewildering and fragmented pricing maze. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 1, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
Doc Re-Used Nasal Surgery Devices; Humira Patent Game; Nonprofit Hospital Tactics
(MedPage Today) -- Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week.
Doc Re-Used Devices for Nasal Surgeries
North Carolina otolaryngologist Anita Louise Jackson... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 1, 2023 Category: American Health Source Type: news
First Humira Biosimilar Launches in US First Humira Biosimilar Launches in US
Amgen ' s Amjevita will be offered at 5% and 55% below Humira ' s list price, but patients may not benefit from the more significant discount.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - January 31, 2023 Category: Internal Medicine Tags: Rheumatology News Source Type: news
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
AbbVie's (ABBV) two-decade Humira monopoly came to an end Tuesday after Amgen (AMGN) launched its biosimilar knockoff at a 55% discount to the original. But AbbVie stock was mostly unmoved. The biosimilar called Amjevita is the first to hit the U.S. market. But through deals with AbbVie, a handful…#abbvie #humira #amgen #amgn #amjevita #murdogordon #abbviestock #richardgonzalez #organon #ogn (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2023 Category: Consumer Health News Source Type: news
Blockbuster AbbVie drug Humira to face competition in US for first time
Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 31, 2023 Category: Pharmaceuticals Source Type: news
AMJEVITA ™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.(1,2) (Source: World Pharma News)
Source: World Pharma News - January 31, 2023 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
'Go big or go home': How a Peninsula biotech looks to win in Humira biosimilar 'feeding frenzy'
The company won't launch its lookalike version of AbbVie's Humira until July, though it was approved by the FDA in December 2021. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 30, 2023 Category: American Health Authors: Ron Leuty Source Type: news
Over $100B in savings? Why the incoming Humira biosimilars will take time to catch on
Endpoints editor and founder John Carroll sat down the Catalent CEO Alessandro Maselli to talk about what’s ahead in 2023. Right or wrong, this covers all the big issues faced by biopharma. This transcript has been edited for brevity and clarity. I think 2022 had to be one of the worst years ever…#johncarroll #catalent #alessandromaselli #federalreserve #unlock (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2023 Category: Consumer Health News Source Type: news
Sunday links: the tools we create
Markets 11 things that zero interest rates enabled including the rise of Cathie Wood. (youngmoney.co) The 'nice-to-have' economy is already in recession. (wsj.com) Why you need a well-articulated investment strategy to ride out tough times. (contessacapitaladvisors.com) AI Everyone is watching for…#cathiewood #aieveryone #google #generativeai #companiesabbvie #abbv #humira #russian #romanabramovich #bnpl (Source: Reuters: Health)
Source: Reuters: Health - January 29, 2023 Category: Consumer Health News Source Type: news
